Faculty

Kristopher R. Bosse, MD

faculty photo
Assistant Professor of Pediatrics
Department: Pediatrics
Graduate Group Affiliations

Contact information
Children's Hospital of Philadelphia
3501 Civic Center Boulevard, CTRB 3050
Philadelphia, PA 19104
Office: 651-492-6726
Fax: 267-426-0685
Education:
BA (Biochemistry )
Bowdoin College, 2002.
MD (Medicine)
University of Pennsylvania Perelman School of Medicine, 2010.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Wolpaw AJ, Grossmann LD, Dessau JL, Dong MM, Aaron BJ, Brafford PA, Volgina D, Pascual-Pasto G, Rodriguez-Garcia A, Uzun Y, Arsenian-Henriksson M, Powell DJ Jr, Bosse KR, Kossenkov A, Tan K, Hogarty MD, Maris JM, Dang CV.: Epigenetic state determines inflammatory sensing in neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America 119(6): e2102358119 February 2022.

Heitzeneder S, Bosse KR, Zhu Z, Zhelev D, Majzner RG, Radosevich MT, Dhingra S, Sotillo E, Buongervino S, Pascual-Pasto G, Garrigan E, Xu P, Huang J, Salzer B, Delaidelli A, Raman S, Cui H, Martinez B, Bornheimer SJ, Sahaf B, Alag A, Fetahu IS, Hasselblatt M, Parker KR, Anbunathan H, Hwang J, Huang M, Sakamoto K, Lacayo NJ, Klysz DD, Theruvath J, Vilches-Moure JG, Satpathy AT, Chang HY, Lehner M, Taschner-Mandl S, Julien JP, Sorensen PH, Dimitrov DS, Maris JM, Mackall CL.: GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity. Cancer Cell 40(1): 53-69, January 2022 Notes: Online ahead of print in December 2021. doi: 10.1016/j.ccell.2021.12.005.

Buongervino SN, Lane MV, Garrigan E, Zhelev DV, Dimitrov DS, Bosse KR.: Antibody-drug conjugate efficacy in neuroblastoma - role of payload, resistance mechanisms, target density, and antibody internalization. Molecular Cancer Therapeutics 20(11): 2228-2239, November 2021 Notes: doi: 10.1158/1535-7163.MCT-20-1034. Epub 2021 Aug 31.

Yarmarkovich M, Marshall QF, Warrington JM, Premaratne R, Farrel A, Groff D, Li W, di Marco M, Runbeck E, Truong H, Toor JS, Tripathi S, Nguyen S, Shen H, Noel T, Church NL, Weiner A, Kendsersky N, Martinez D, Weisberg R, Christie M, Eisenlohr L, Bosse KR, Dimitrov DS, Stevanovic S, Sgourakis NG, Kiefel BR, Maris JM.: Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs. Nature 599(7885): 477-484, November 2021 Notes: doi: 10.1038/s41586-021-04061-6. Epub 2021 Nov 3.

Raman S, Buongervino SN, Lane MV, Zhelev DV, Zhu Z, Cui H, Martinez B, Martinez D, Wang Y, Upton K, Patel K, Rathi KS, Navia CT, Harmon DB, Li Y, Pawel B, Dimitrov DS, Maris JM, Julien JP, Bosse KR.: A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope. Cell Reports Medicine 2(7), July 2021.

Foster JB, Bosse KR, Griffin C, Stern A, Brimley C, Storm PB, Barrett D, Maris JMM, Resnick AC: Use of mRNA CAR T cells for malignant pediatric brain tumors. Present at the American Society of Pediatric Hematology Oncology (ASPHO) Annual Meeting April 2021.

Heitzeneder S, Bosse KR, Zhongyu Z, Dontcho J, Dhingra S, Majzner RG, Sotillo E, Buongervino S, Xu P, Huang J, Delaidelli A, Hasselblatt M, Parker K, Anbunathan H, Alag A, Hwang J, Huang M, Klysz DD, Theruvath JL, Vilches-Moure JG, Satpathy AT, Sorensen PH, Dimitrov DS, Maris JM, Mackall CM. : Potent activity of CAR T cells targeting the oncofetal protein GPC2 engineered to recognize low antigen density in neuroblastoma. American Association of Cancer Research (AACR) Annual meeting April 2021.

Pascual-Pasto G, Buongervino SN, Zhelev DV, Erbe AK, Sondel P, Dimitrov D, Bosse KR : The antibody-drug conjugate D3-GPC2-PBD induces immunogenic cell death and triggers antitumor immune responses in preclinical neuroblastoma models Advances in Neuroblastoma Research Congress January 2021.

Raman S, Buongervino SN, Lane M, Zhelev DV, Zhu Z, Cui H, Martinez B, Martinez D, Wang Y, Upton K, Patel K, Rathi KS, Pawel B, Dimitrov DS, Maris JM, Julien J-P, Bosse KR : The antibody drug conjugate D3-GPC2-PBD is potently efficacious against diverse preclinical models of neuroblastoma and other cancers via engagement of a tumor-specific conformational GPC2 epitope Advances in Neuroblastoma Research Congress January 2021.

Buongervino S, Lane M, Garrigan E, Pascual-Pasto G, Martinez D, Zhelev DV, Dimitrov DS, Bosse KR: Defining the elements of antibody-drug conjugate efficacy in neuroblastoma. Advances in Neuroblastoma Research Congress January 2021.

back to top
Last updated: 08/03/2022
The Trustees of the University of Pennsylvania